We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shares in Newron Pharmaceuticals have taken a massive hit from the failure of sarizotan to show a clear benefit in patients with Rett syndrome, a severe neurodevelopmental disorder primarily affecting females.